Clinical trials: Tailored Condition
Atrial Fibrillation
Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation
The purpose of this study is to determine whether it is safe to stop anticoagulation medication in patients with a history of atrial fibrillation (AF) based on information from a pacemaker or implantable cardioverter…
- Trial name
- TACTIC AF (NCT01650298)
- Testing
- Drug (Direct thrombin or Factor Xa inhibitor)
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation
Atrial Fibrillation (AF) ablation is typically performed in predefined anatomic regions of the left atrium without attempting to identify patient-specific areas of interest.
- Trial name
- Tailored-AF (NCT04702451)
- Testing
- Dispersion ablation + PVI, VX1, PVI
- Where
- 26 sites in United States, Belgium and 3 more
- Volunteers
- 377 people
- Sponsor
- Volta Medical
Psoriasis
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
The purpose of the study is to assess the effect of extending maintenance dosing intervals beyond 12 weeks on the clinical efficacy and safety of ustekinumab in subjects with moderate-to-severe plaque psoriasis.
- Trial name
- PSTELLAR (NCT01550744)
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- 40 sites in United States
- Volunteers
- 478 people
- Sponsor
- Janssen Biotech, Inc.
Ovulation Induction
Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction
This is an open-label, prospective, randomized, controlled, multicentric, multinational, phase IV study to evaluate the use of Gonal-f in inducing ovulation in female subjects with chronic anovulation.
- Trial name
- NCT01081626
- Testing
- Recombinant FSH (follitropin alpha)
- Where
- 3 sites in Kuwait, Lebanon and 1 more
- Volunteers
- 310 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Severe Haemophilia A
Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A
To compare the number of breakthrough bleeds under tailored prophylaxis with Human cell line recombinant factor FVIII (Human-cl rhFVIII) with the historical bleeding rate from patients who received Human-cl rhFVIII as on demand…
- Trial name
- NCT01863758
- Testing
- Human-cl rhFVIII
- Where
- 20 sites in Austria, Bulgaria and 6 more
- Volunteers
- 66 people
- Sponsor
- Octapharma
Infertility, Monofollicular Development
Low-dose Gonal-f® in Ovulation Induction
This is a prospective, multicenter, open-label, comparative and parallel-group study of ovulation induction evaluating tailoring of Recombinant follicle stimulating hormone (FSH) treatment using the Gonal-f® prefilled pen in…
- Trial name
- LoGo (NCT01871532)
- Testing
- Gonal-f®
- Where
- 10 sites in Ireland, United Kingdom
- Volunteers
- 24 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Atrial Fibrillation
Tailored Treatment of Permanent Atrial Fibrillation
The purpose of this trial is to evaluate the safety and efficacy of the Medtronic Cardiac Ablation System compared to medical therapy in the persistent and long-standing persistent atrial fibrillation population.
- Trial name
- TTOP-AF (NCT00514735)
- Testing
- Medtronic Cardiac Ablation System, Class I or III Antiarrhythmic Medications
- Where
- 24 sites in United States, Netherlands
- Volunteers
- 210 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Hepatitis C, Chronic
Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)
This is an Australian, open-label, multicenter, randomized, double-blind clinical trial designed to assess the efficacy of combination therapy with pegylated interferon alfa-2b and ribavirin for 48 weeks versus 24 weeks in the…
- Trial name
- NCT00255034
- Testing
- Peginterferon alfa-2b, Ribavirin
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Type 2
Evaluation of a Closed-loop Insulin Delivery System at Home With Tailored Home Care Services in Poorly Controlled Type 2 Diabetes Patients (T2D)
Closed-loop insulin delivery system has the potential to improve the condition of many poorly controlled insulin-treated Type 2 Diabetes (T2D) patients.
- Trial name
- CLOSEAP+ (NCT04233229)
- Testing
- t:slim X2 with Control-IQ, home healthcare services, usual care for daily insulin treatment
- Where
- 10 sites in France
- Volunteers
- 43 people
- Sponsor
- Air Liquide Santé International
Hypertension
Tailored Drug Titration Using Artificial Intelligence
The purpose of the ARTERY Outcomes study is to compare optima-for-blood pressure (optima4BP), a clinical decision support system for hypertension (HTN) treatment optimization to standard of care in patients with essential HTN.
- Trial name
- NCT04223934
- Testing
- optima4BP
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Optima Integrated Health